Breaking News, Trials & Filings

EU Clears Bristol Myers Squibb’s Breyanzi for Mantle Cell Lymphoma

Marks Breyanzi’s fourth indication in Europe, adding to existing approvals for several aggressive B-cell lymphomas.

Author Image

By: Charlie Sternberg

Associate Editor

The European Commission (EC) has granted approval to Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. “This approval for Breyanzi in relapsed or refractory mantle cell lymphoma marks another important step as we continue t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters